# Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

> **NCT05101109** · PHASE1 · COMPLETED · sponsor: **ABL Bio, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ABL501

## Key facts

- **NCT ID:** NCT05101109
- **Lead sponsor:** ABL Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2024-05-14
- **Final completion:** 2024-05-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101109, "Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05101109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*